|
Characteristics
|
Number
|
%
|
|---|
|
Age (years)
|
|
Median (IQR)
|
61 (18)
| |
| ≦60 |
24
|
49.0
|
|
> 60
|
25
|
51.0
|
|
Gender
|
|
Male
|
22
|
44.9
|
|
Female
|
27
|
55.1
|
|
Performance status
|
|
0
|
29
|
59.2
|
|
1
|
13
|
26.5
|
|
2
|
6
|
12.2
|
|
3
|
1
|
2.0
|
|
Location of primary site
|
|
Extremities
|
18
|
36.7
|
|
Head and neck
|
9
|
18.4
|
|
Trunk
|
16
|
32.7
|
|
Unknown
|
6
|
12.2
|
|
Type
|
|
Acral melanoma
|
15
|
30.6
|
|
Non-acral cutaneous melanoma
|
5
|
10.2
|
|
Mucosal melanoma
|
16
|
32.7
|
|
Others
|
7
|
14.3
|
|
Unknown
|
6
|
12.2
|
|
Stage
|
|
3
|
6
|
12.2
|
|
4, M1a
|
5
|
10.2
|
|
4, M1b
|
8
|
16.3
|
|
4, M1c
|
30
|
61.2
|
|
BRAF gene mutation
|
|
No
|
34
|
69.4
|
|
Yes
|
9
|
18.4
|
|
Unknown
|
6
|
12.2
|
|
Treatment regimen
|
|
Nivolumab
|
33
|
67.3
|
|
Pembrolizumab
|
16
|
32.7
|
|
Immunotherapy therapy
|
|
First-line
|
31
|
63.3
|
|
Second-or later-line
|
18
|
36.7
|
|
Response
|
|
CR
|
2
|
4.1
|
|
PR
|
3
|
6.1
|
|
SD
|
9
|
18.4
|
|
PD
|
29
|
59.2
|
|
N/A
|
6
|
12.2
|
- IQR interquartile range, CR complete response, PR partial response, SD stable disease, PD progressive disease, N/A not assessed
